Full Legal Name |
Commercial Interest |
Role |
Level of Participation in the Activity |
Clarissa Baldotto |
1. AstraZeneca, Amgem, Janssen (Johnson & Johnson), Roche, BMS, Immunocore 2. AstraZeneca, Pfizer, Amgem, Janssen (Johnson & Johnson), Roche, Takeda, MSD 3. AstraZeneca, Pfizer, Amgem, Janssen (Johnson & Johnson), Roche |
1. Research (Funding paid to institution) 2. Consultant 3. Advisor |
Moderator |
Hidehito Horinouchi |
1. Abbvie, Amgem, AstraZeneca, BMS, Chugai/Roche, Daiichi-SanykoMSD, Ono, Natera 2. Abbvie, AstraZeneca, Chugai/Roche, BMS, Ono, Boehringer Ingelheim |
1. Research (Funding paid to institution) 2. Advisor |
Planner |
Calvin Ng |
1. Johnson & Johnson, Medtronic, Noah Medical, Cook Medical |
1. Consultant |
Moderator |
Sanja Dacic |
1. AstraZeneca |
1. Consulant, Advisor |
Speaker |
Myung-Ju Anh |
None |
N/A |
Speaker |
Catherine Shu |
1. AstraZeneca, JNJ, EMD Serono, Gilead |
1. Consultant |
Speaker |
Lauren Byers |
1. AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical Co., Daiichi Sankyo, Genentech Inc., Jazz Pharmaceuticals, Novartis, Puma Biotechnology 2. AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim,Chugai Pharmaceutical Co., Daiichi Sankyo, Genentech Inc., Jazz Pharmaceuticals, Novartis, Puma Biotechnology Honoraria: Clinical Care Options, UpToDate 3. Patents, Royalties, Other Intellectual Property: Molecular subtyping of small cell lung cancer to predict therapeutic responses (U.S. Patent No: 11,732,306); methods and systems for diagnosis, classification, and treatment of small cell lung cancer and other high grade neuroendocrine carcinomas. 4. Amgen, AstraZeneca, Bristol Myers Squibb |
1. Advisor 2. Consultant 3. Royalties/Intellectual Property 4. Research funding |
Speaker |